Aerie pharmaceuticals submits marketing authorisation application for roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in europe

Aerie pharmaceuticals, inc. announced that it has submitted the marketing authorisation application (maa) for roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the european medicines agency (ema). should the maa for roclanda® be accepted for review by the ema, an opinion from the committee for medicinal products for human use is expected in approximately 12 months. roclanda® is currently marketed in the united states as rocklatan®. the maa submission for roclanda® was predicated on the receipt of a marketing authorisation for rhokiinsa® (netarsudil ophthalmic solution) 0.02%, which the european commission granted in november 2019. rhokiinsa® is marketed as rhopressa® in the united states.
AERI Ratings Summary
AERI Quant Ranking